Now I have all the information I need. Let me compile the final consolidated review.

---

## Summary

This paper proposes a conformal prediction method for constructing lower prediction bounds (LPBs) on counterfactual survival times under general right-censoring. The core technical contribution is a reweighting scheme that, under strong ignorability, transforms the counterfactual survival LPB problem into a weighted conformal inference task. This enables an exact marginal coverage guarantee (up to weight estimation error), advancing over prior PAC-type guarantees. A doubly robust property (Theorem 4.2) shows asymptotic coverage holds if either the weight function or the quantile estimator is consistent. Experiments on six synthetic settings and a real lung-cancer clinical dataset demonstrate valid coverage and more informative bounds than baselines.

## Strengths

- **Novel reweighting calibration for counterfactual survival LPBs:** The paper's key insight — transforming the coverage probability via Equation (1) into a reweighted expectation over uncensored observations with $W=w, e=1$, then applying weighted conformal prediction — is original and well-motivated. This elegantly bridges the counterfactual survival setting with existing weighted conformal machinery and yields an exact (not PAC) marginal coverage guarantee, directly improving on Davidov et al. (2025).

- **Solid theoretical contributions:** Theorem 4.1 provides a finite-sample bound on the coverage gap in terms of the expected absolute error in weight estimation ($\frac{1}{2}\mathbb{E}[|\tilde{\omega}(X) - \omega(X)|]$), giving a precise and interpretable error quantification. Theorem 4.2 establishes asymptotic double robustness: coverage holds if either $\hat{\gamma}(x)$ or $\hat{q}_\alpha^{(w)}(x)$ is consistently estimated. These provide meaningful theoretical backing beyond what is typical in applied conformal work.

- **Comprehensive synthetic evaluation with consistent results:** Across all six simulation settings (Figure 1), the method maintains empirical coverage close to the nominal 90% level while producing higher relative LPB than the focused and fused baselines from Davidov et al. (2025). The robustness experiment (Figure 3) is particularly compelling: when 10% of survival times are perturbed by outliers, only the proposed method preserves the target coverage while PAC-guarantee baselines drop substantially.

- **Clinically interpretable real-data results:** On 541 non-small cell lung cancer patients, LPBs differ across radiochemotherapy regimens in clinically meaningful ways: VMAT yields higher LPBs than IMRT, and induction/concurrent chemotherapy improves LPBs (Figure 4). Covariate-stratified LPBs align with known prognostic factors (stage, KPS, tumor diameter — Figure 5), demonstrating the method's potential for personalized treatment selection.

- **Clear algorithmic presentation:** Algorithm 1 concisely summarizes the data splitting, weight estimation, non-conformity score computation, and weighted quantile calibration steps, making the method implementable.

## Weaknesses

### Fatal

None.

### Major

- **τ-optimization lacks coverage justification.** The paper states "our procedure yields a prediction set that satisfies the coverage guarantee for any τ ∈ (0,1)" and then, for each test point $x$, selects $\tau^*(x) := \arg\max_\tau (\tilde{q}_\tau^{(w)}(x) - c_{1-\alpha}^{(w)}(\tau))$ to maximize the LPB. The guarantee for each fixed τ does not extend to the data-dependent maximum: since $\tilde{L}(x, \tau^*(x)) \geq \tilde{L}(x, \tau)$ for all τ, the coverage of the optimized LPB can only be worse than or equal to that of any individual τ. The calibration threshold $c_{1-\alpha}^{(w)}(\tau)$ itself depends on the calibration data, so the selection is not simply a post-hoc choice among independently valid bounds. The paper provides no theoretical analysis of post-selection coverage, and the headline claim that the procedure yields a valid LPB does not distinguish between the guaranteed fixed-τ procedure and the actually-deployed optimized-τ procedure. Empirical results (Table 1) suggest the gap may be modest in practice, but the mismatch between claim and method is a genuine gap that needs to be addressed — either by proving the guarantee survives optimization, or by clearly separating the guaranteed fixed-τ procedure from the heuristic optimization.

- **Real-data coverage evaluation methodology is unclear.** The real clinical dataset contains right-censored observations, meaning the true survival time $T$ is unobserved for many test subjects. The paper reports empirical coverage rates near 0.9 (Figure 4 top row) but does not explain how coverage is computed when $T$ is censored. If the evaluation is restricted to uncensored test cases ($e=1$), the computed rate estimates $\mathbb{P}(\text{covered} \mid e=1)$ rather than the marginal $\mathbb{P}_{X,T(w)}(\text{covered})$ that the method targets. Since the censoring mechanism may correlate with survival, this conditional coverage can differ systematically from the marginal coverage the paper claims to guarantee. Without clarification or correction (e.g., inverse-probability-of-censoring weighting on the test set), the real-data evidence for the marginal coverage guarantee is insufficient.

### Minor

- **"Exact" language in the abstract overstates the guarantee.** The abstract claims an "exact miscoverage guarantee," but Theorem 4.1 shows the coverage error is bounded by $\frac{1}{2}\mathbb{E}[|\tilde{\omega}(X) - \omega(X)|]$. The guarantee is only exact when the density ratio $\omega(x)$ is known; in practice it is estimated and the error term can be non-negligible. The language should be tempered to "finite-sample bound" or "distribution-free guarantee with weight-estimation error."

- **"Relative LPB" is never defined in the main text.** This metric appears in every experimental figure (Figures 1–5) and is the primary measure of bound informativeness, yet its definition (what the LPB is divided by for normalization) is absent. A reader cannot judge whether higher relative LPB genuinely corresponds to more informative bounds without knowing the normalization.

- **The derivation of inequality (iii) in Equation (1) lacks standalone clarity.** The critical step that yields the upper bound is attributed to "the proof of Lemma A.1 conditional on $X=x, W=w$" without any sketch of the reasoning. While the lemma likely exists in the appendix, the main text should contain enough exposition for the reader to follow the core derivation without consulting supplementary material.

- **Theorem 4.2 condition (A2) plausibility is not discussed.** Condition A2 requires uniform bounds on the density of $T(w)$ near the quantile and specific convergence behavior of quantile errors weighted by $\hat{\gamma}(x)^{-1}$. These are fairly specific technical conditions; a brief discussion of when they are likely to hold in practice would strengthen the theoretical contribution.

- **LPB treatment comparisons should acknowledge they reflect lower bounds only.** The paper interprets higher LPB under VMAT vs. IMRT as evidence of treatment benefit (Section 5.2). This inference is reasonable but the text should note that an LPB difference reflects a shift in the lower bound, not necessarily the full survival distribution — a treatment could have a higher LPB but worse upper-tail outcomes.

### Trivial

None.

## Nice-to-Haves

- **Fix τ as default, present optimization as heuristic.** One straightforward resolution to the τ-optimization concern: present the method with a fixed τ (say $\tau = \alpha$) and the full coverage guarantee, then present the τ-optimization as an empirical enhancement whose coverage properties should be validated via simulation. This preserves the core contribution while being transparent about limitations.

- **Show continuous covariate adaptiveness.** Figure 5 binarizes all covariates. Showing how LPB varies continuously with important predictors (e.g., KPS, tumor diameter) would better illustrate the method's personalization capability.

- **Report estimated $\mathbb{E}|\hat{\omega} - \omega|$ from synthetic experiments** to give readers a concrete sense of the bound in Theorem 4.1.

- **Brief computational cost discussion** comparing the weighted conformal approach to the adaptive cut-off baselines would round out the practical comparison.

## Removed Points

These points are flagged to be removed; treat them with caution.

- **Harsh critic: "The derivation... is not explained in the main text (a lemma is cited)."** → This was partially retained (Minor weakness 3 above) but downgraded from a more serious critique. The paper does sketch the derivation in Equation (1); the issue is only that step (iii) is delegated to an appendix lemma without any standalone sketch. This is a presentation issue, not a soundness one.

- **Harsh critic: "does not discuss the computational cost or the complexity of implementing the weighting scheme."** → Moved to Nice-to-Haves. Computational cost is not central to the paper's claims.

- **Harsh critic: "Figure 5 uses binarized covariates. It would be more informative to show how LPB varies continuously."** → Moved to Nice-to-Haves. This is a suggestion for richer visualization, not a methodological weakness.

- **Strength Finder: "Optimization of the quantile index τ... Table 1 shows that optimizing τ yields noticeably larger LPBs... while coverage remains above the nominal level."** → This strength conflicts with the verified Major weakness about the τ-optimization lacking coverage justification. The empirical observation is noted, but it should not be presented as an unqualified strength.

- **Strength Finder generic strengths** about "Clear algorithmic formulation" — retained as a supporting strength since Algorithm 1 is indeed clearly presented and specific to this paper.

- **Harsh critic: concern about "missing appendix" or "appendix-deferred proofs."** → Removed per hard rules. The parser strips the appendix; it exists in the original submission.

## Novel Insights

The review process surfaced an important tension in this work that is worth flagging as a general lesson for conformal methods: when a conformal procedure guarantees coverage for each member of a parameterized family of prediction sets, optimizing the parameter per test point to maximize informativeness is not a free lunch. The coverage of the pointwise maximum is bounded above by the coverage of any individual set, and without an explicit post-selection correction (e.g., union bound over a grid, additional data split), the guarantee evaporates. This is not unique to this paper — it applies to any conformal method that tunes a parameter post-calibration — but it is especially salient here because the optimization is the final step that produces the bound the user actually sees. Future work on conformal prediction with data-dependent parameter selection should either provide post-selection coverage guarantees or clearly label the optimization as heuristic.

## Suggestions

- The most impactful revision would be to either prove that the coverage guarantee survives the τ-optimization (e.g., via a union bound over a discrete τ-grid with appropriate correction), or to restructure the paper so that the guaranteed procedure (fixed τ) is clearly separated from the optimized heuristic. The former would strengthen the paper considerably; the latter is a simpler fix that preserves the core contribution.

- Clarify the real-data coverage computation. If coverage is evaluated only on uncensored test points, state this explicitly and discuss the gap between conditional and marginal coverage. Better still, apply inverse-probability-of-censoring weighting on the test set to estimate the marginal coverage rate.

- Define "relative LPB" explicitly in Section 5.

- Temper the "exact" language in the abstract to reflect the weight-estimation error term in Theorem 4.1.

- Add a sentence or two discussing when condition A2 in Theorem 4.2 is plausible in practice.

## Score and Decision

### Calibration anchors

| Anchor | Avg Score | Round | Comparison |
|--------|-----------|-------|------------|
| JQtuCumAFD ("Conformalized Survival Analysis for General Right-Censored Data") | 5.50 | 1 (mid) | Closest prior work (Davidov et al. baseline). PAC-type guarantee, no counterfactual dimension. Our paper is clearly stronger: exact guarantee + counterfactual + doubly robust. |
| pVL4bYKOGM ("Conformal prediction for causal effects of continuous treatments") | 5.50 | 1 (mid) | Conformal for counterfactuals but continuous treatments, different setting. Rejected for evaluation issues. Our paper has more comprehensive experiments. |
| AKAz88zYLB ("Conformal Prediction for Dose-Response Models") | 5.80 | 1 (mid) / 2 (low) | Weighted CP for counterfactuals but no theoretical guarantees. Our paper is theoretically stronger. |
| Nfd7z9d6Bb ("Probabilistic Conformal Prediction with Approximate Conditional Validity") | 6.00 | 2 (low) | Solid CP paper with all-6 scores. Our paper addresses a more challenging setting (counterfactual + censoring), has stronger theory, and comparable experiments. Our paper is somewhat stronger. |
| 1mNFsbvo2P ("Domain constraints improve risk prediction when outcome data is missing") | 7.25 | 2 (high) | Strong paper with creative domain constraints and real healthcare data. Our paper does not quite reach this level due to the τ-optimization gap and real-data evaluation concerns. |
| fZK6AQXlUU ("Conformal Prediction Sets Can Cause Disparate Impact") | 7.25 | 2 (high) | Very strong paper with human subjects. Different category. Our paper is below this level. |

**Round 1 bracket:** 5.5–7.5, leaning toward the upper half. The paper clearly improves on the 5.50 anchor (Davidov et al.) and the 5.80 anchor (dose-response CP without theory). The 7.25+ anchors are papers with fewer methodological gaps.

**Round 2 narrowing:** The paper sits between the 6.00 anchor (Nfd7z9d6Bb, a solid CP paper with some limitations) and the 7.25 anchors (papers with very strong contributions and few concerns). The τ-optimization gap and real-data coverage evaluation issues prevent it from reaching the 7+ tier, but the core contribution — reweighted conformal calibration for counterfactual survival LPBs with finite-sample and doubly robust guarantees — is more novel and better supported than the 6.00 anchor. The paper also has a real clinical application that most 6.0-level CP papers lack.

**Final score: 6.5.** The paper makes a clear, novel contribution to conformal prediction for counterfactual survival analysis with solid theory and comprehensive experiments. The two major weaknesses (τ-optimization gap, real-data evaluation clarity) are addressable and do not invalidate the core methodology, but they do prevent the paper from reaching the top tier.

MY FINAL SCORE: <score>6.5</score>
MY FINAL DECISION: <decision>Accept</decision>